Skip to content
News Center
About Us Careers News Center Contact Us Legal Video Hub iHope Doing Business with Illumina Investors Illumina for Startups Home

Perspectives Blog

2 min read
Illumina’s Diversity, Equity, and Inclusion Actions Earn External Recognition and Further Advance Our Culture of Care
By Dr. Lisa Toppin , Global Head of Diversity and Inclusion January 27, 2022
4 min read
2021 in Genomics
By Francis deSouza , CEO
December 30, 2021
2 min read
When it Comes to Diversity, Awareness is No Longer Enough
By Dr. Lisa Toppin , Global Head of Diversity and Inclusion
October 6, 2021
2 min read
Empowering Informed Choices That Can Change Lives
By Gretchen Weightman , General Manager — Asia Pacific & Japan
June 30, 2021
3 min read
Reflections on a Long-term Collaboration to Drive Rapid Whole Genome Diagnostics
By Kevin Hall, Senior Director, Development June 16, 2021
3 min read
Security and Scale in The Era of Genomics Data Discovery
By Susan Tousi, Chief Commercial Officer June 8, 2021
3 min read
Solving for the Information Gap in Genomics Breakthroughs
By Hans Cobben, VP, Software Development January 28, 2021
1 min read
MLK Day 2021: Turning Hope into Action
By Dr. Lisa Toppin, VP, Diversity and Inclusion January 14, 2021
11 min read
2020 in genomics: a global pandemic and groundbreaking scientific developments
By Francis deSouza, CEO December 13, 2020
4 min read
Reflecting on the Human Genome Project
By Susan Tousi, SVP, CPO October 26, 2020
1 min read
More expectant parents to get access to non-invasive prenatal testing
By Dr. Phil Febbo, SVP, CMO October 9, 2020
6 min read
Illumina's COVID testing service
By Dr. Phil Febbo, SVP, CMO September 3, 2020
2 min read
Every voice raised against racism chips away at its power
By Francis deSouza, CEO June 30, 2020
3 min read
Illumina and BlueBee: Unlocking the full potential of genomic insights
By Susan Tousi, SVP, CPO June 18, 2020
2 min read
Illumina receives first FDA emergency use authorization for a sequencing based COVID-19 diagnostic test
By Susan Tousi, SVP, CPO June 9, 2020
3 min read
The role of genomics in the COVID-19 pandemic, today and in the future
By Dr. Phil Febbo, SVP, CMO June 8, 2020
2 min read
Standing up and speaking out for equality and justice
By Susan Tousi, SVP, CPO June 3, 2020
4 min read
Something to roar about
By Susan Tousi, SVP, CPO May 19, 2020
2 min read
DNA Day in the time of COVID-19
By Francis deSouza, CEO April 25, 2020
2 min read
Delivering world-class solutions to combat COVID-19
By Susan Tousi, SVP, CPO April 16, 2020
5 min read
How sequencing-based surveillance helps fight COVID-19
By Dr. Phil Febbo, SVP, CMO March 31, 2020
2 min read
Why You Should Care about Rare Disease Day
By Francis deSouza, CEO February 24, 2020
3 min read
Helping the heroes on the front lines of the SARS-CoV-2 battle
By Francis deSouza, CEO February 18, 2020
2 min read
How sequencing helps solve the "unknown" of novel viral outbreaks
By Francis deSouza, CEO February 13, 2020
4 min read
Partnerships catalyze patient access to genomic testing
By Dr. Phil Febbo, SVP, CMO January 13, 2020
5 min read
The power and promise of liquid biopsies
By Dr. Phil Febbo, SVP, CMO November 6, 2019
5 min read
The complex world of pan-cancer biomarkers
By Dr. Phil Febbo, SVP, CMO September 26, 2019

Driving innovation for a healthy future

@illumina

In the News

Date Publication Title
Apr 12, 2024 Reuters EU approves Illumina's plan to divest cancer test maker Grail
Apr 10, 2024 San Diego Union Tribune Illumina gets two new executives as the San Diego biotech revamps its C-suite
Apr 9, 2024 GEN News Best of NGS: The Instrument Companies to Watch
View All Illumina News
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.